Massive stroke drug study shows Real-World results
NCT ID NCT06707987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a clot-dissolving drug called non-immunogenic staphylokinase in over 23,000 adults who had an acute ischemic stroke within the last 4.5 hours. The goal was to see how safe and effective the drug is in everyday hospital practice. Researchers measured how many patients had little or no disability 90 days after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Federal Brain and Neurotechnology Center
Moscow, 117513, Russia